Abstract
Delayed hemolysis is an uncommon reaction to intravenous artesunate for the treatment of severe malaria. We report a case of a patient who developed severe malaria after initial inadequate treatment, thus requiring IV artesunate therapy. Delayed hemolytic anemia then occurred and was monitored for weeks after completion of treatment.
Highlights
Malaria is a vector-borne infectious parasite that is transmitted through mosquitoes
According to the World Health Organization (WHO), there are about 2,000 cases of malaria reported in the United States annually, predominantly reported from travelers returning from these regions [1]
Intravenous artesunate is the first-line defense against severe malaria throughout the world, and post-artemisinin delayed hemolytic anemia (PADH) is a rare occurrence
Summary
Malaria is a vector-borne infectious parasite that is transmitted through mosquitoes. If post-artemisinin delayed hemolytic anemia (PADH) occurs, patients need routine lab work done for four weeks following to monitor hemoglobin, reticulocyte count, haptoglobin, lactate dehydrogenase, and total bilirubin [2]. Intravenous artesunate is the first-line defense against severe malaria throughout the world, and PADH is a rare occurrence The goal of this case report is to track the symptoms and progress of a patient who developed hemolytic anemia following IV artesunate treatment for severe malaria. Lactate dehydrogenase down to 192 U/L from 217 U/L, hemoglobin was up to 11.4 g/ dL from 10.1 g/dL when measured the week previous These values indicate that our patient did experience delayed hemolytic anemia following intravenous artesunate treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
